Foundaio: SFDA Opens the Door to Next-Generation Obesity Treatment
As the global demand for safer, more accessible, and effective obesity treatments continues to surge, Saudi Arabia is stepping forward with bold initiatives to deliver innovative healthcare solutions.
A New Chapter in Chronic Weight Management
In a remarkable milestone, the Saudi Food and Drug Authority (SFDA) has approved the registration of Foundaio, a once-daily oral medication meticulously designed to support long-term weight loss and weight maintenance in adults living with obesity or overweight who also face at least one weight‑related medical condition.
By approving this breakthrough therapy, the SFDA introduces a revolutionary option that seamlessly combines the convenience of an oral therapy with a long-term approach to chronic weight management.
What Makes Foundaio Different from Traditional GLP-1 Therapies?
Foundaio builds on an advanced approach that unites pharmaceutical innovation with lifestyle-based care in a single daily tablet.
Powered by the active ingredient orforglipron, the medication effectively activates GLP-1 receptors to help regulate appetite and blood sugar levels. This mechanism enables patients to consume fewer calories and maintain achieve weight loss.
When complemented by a healthy diet and regular exercise, the therapy stands out as a needle-free alternative that could promote long-term adherence for many eligible patients.
How Compelling Is the Clinical Proof?
The regulatory approval followed an extensive scientific assessment to verify Foundaio’s safety, efficacy, and overall quality.
To ensure robust results, the decision was reinforced by two pivotal Phase 3 clinical trials, each conducted over 72 weeks, which provided strong evidence of the medication’s effectiveness in long-term weight management.
Together, the studies showed the therapy’s ability to support sustained weight loss.
In the first trial, involving 3,127 adults with obesity but without diabetes, individuals taking the highest evaluated 36 mg dose recorded an average body weight reduction of 11.2%, compared with 2.1% in the placebo group.
The second trial, which consisted of 1,613 adults with obesity and Type 2 diabetes, reported an average weight reduction of 9.6% among patients receiving the same dose, versus 2.5% in the placebo group.
What Side Effects Were Most Common?
The SFDA emphasized that the medication demonstrated a generally manageable safety profile during clinical trials, noting that the most commonly reported side effects were gastrointestinal, including nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain.
Some participants also experienced abdominal bloating, hair loss, and fatigue.
Fortunately, most gastrointestinal symptoms were mild to moderate and primarily occurred during dose escalation, improving over time as treatment progressed.
Why Is Medical Supervision Essential?
Emphasizing the importance of responsible use, the SFDA underscored that Foundaio should be prescribed and monitored exclusively by healthcare professionals, with patients undergoing regular follow-up throughout the course of treatment.
The authority also warned against its use in patients with a personal or family history of certain thyroid cancers or related hereditary syndromes.
Related Topics:
SFDA Highlights Support for Researchers, Innovators at World Creativity Day Exhibition
Abdominal pain? It can be irritable bowel syndrome
Hajj 2026: SFDA Laboratories Operate 24/7 to Ensure Pilgrims Safety
